Carboprost versus Oxytocin as the first-line treatment of primary postpartum haemorrhage (COPE): protocol for a phase IV, double-blind, double-dummy, randomised controlled trial and economic analysis
BMJ Open · 2025
DOI: 10.1136/bmjopen-2025-101255 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift BMJ Open, 2025. Verfasst von Charlotte Van Netten und 26 weiteren Autor:innen. Beteiligte Einrichtung: Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK. Hauptthemen laut MEDLINE: Postpartum Hemorrhage, Oxytocin, Oxytocics, Carboprost. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Technology Assessment Programme.
Abstract (Originalsprache)
Introduction Excessive bleeding after childbirth (postpartum haemorrhage, PPH) affects 5% of births and causes 75 000 maternal deaths worldwide annually. It is the leading cause of direct maternal deaths globally and continues to be a major cause of mortality in the UK. Oxytocin is the standard first-line treatment for atonic PPH. The PPH rate is increasing, and this may be partially related to the overuse of oxytocics in labour. Laboratory studies on myometrium suggest that repeated use of oxytocics leads to the saturation of oxytocin receptors and reduced therapeutic efficacy of oxytocin. Carboprost (a prostaglandin analogue) is usually reserved for second-line management of atonic PPH. A systematic review comparing the efficacy of carboprost and conventional uterotonics for PPH prophylaxis found that carboprost was associated with less blood loss, but around 15% of women experienced side effects. The study’s aim is to compare intramuscular carboprost with intravenous oxytocin for the initial treatment of PPH. In addition, to assess the cost-effectiveness of both treatments, participants’ views on the two treatments and the consent process. Methods and analysis COPE is a double-blind, double-dummy, randomised controlled trial that aims to recruit 2000 women (1:1 allocation, stratified by mode of birth) across 20 hospitals in the UK. Due to the emergency nature of PPH, COPE uses a research without prior consent (RWPC) model. Randomisation and treatment will occur if eligibility criteria are met once bleeding starts. Postnatal consent will be sought for disclosure of identifiable data and continued follow-up. Clinical efficacy outcomes will be collected at 24 and 48 hours or at hospital discharge, if sooner. Questionnaires will also be collected at 24 hours and 4 weeks postrandomisation. Cost-effectiveness will be based on the incremental cost per quality-adjusted life-year, calculated from the perspective of the NHS and personal social services. Ethics and dissemination This study has been approved by the Coventry and Warwickshire Research Ethics Committee (REC) (18/WM/0227) and the Health Research Authority. Results will be disseminated via peer-reviewed publications. Trial registration number NCT16416766 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK.
- Department of Women's and Children's Health, University of Liverpool, Liverpool, UK.
- School of Medicine & Population Health, The University of Sheffield, Sheffield, UK.
- Caring Futures Institute, Flinders University, Bedford Park, South Australia, Australia.
- Institute of Infection and Immunity, Cardiff University, Cardiff, UK.
- University Hospital of Wales, Cardiff, UK.
Förderung
- Health Technology Assessment Programme
Zitieren
APA
Van Netten, C., Vallabhaneni, K., Hardwick, B., Anumba, D., Briley, A. L., Collins, P., Collis, R. E., Deja, E., Gkioni, E., Gyte, G., Hickey, H., Hinshaw, K., Hughes, D. A., Kenyon, S., Lavender, T., Meher, S., Plumpton, C., Robson, S., Rosala-Hallas, A., …, & Weeks, A. (2025). Carboprost versus Oxytocin as the first-line treatment of primary postpartum haemorrhage (COPE): protocol for a phase IV, double-blind, double-dummy, randomised controlled trial and economic analysis. BMJ Open. https://doi.org/10.1136/bmjopen-2025-101255
Vancouver
Van Netten C, Vallabhaneni K, Hardwick B, Anumba D, Briley AL, Collins P, et al. Carboprost versus Oxytocin as the first-line treatment of primary postpartum haemorrhage (COPE): protocol for a phase IV, double-blind, double-dummy, randomised controlled trial and economic analysis. BMJ Open. 2025. doi:10.1136/bmjopen-2025-101255
BibTeX
@article{VanNetten2025,
author = {Van Netten, Charlotte and Vallabhaneni, Kirtana and Hardwick, Ben and Anumba, Dilly and Briley, Annette L and Collins, Peter and Collis, Rachel E and Deja, Elizabeth and Gkioni, Efstathia and Gyte, Gillian and Hickey, Helen and Hinshaw, Kim and Hughes, Dyfrig A and Kenyon, Sion and Lavender, Tina and Meher, Shireen and Plumpton, Catrin and Robson, Stephen and Rosala-Hallas, Anna and Saviciute, Egle and Shennan, Andrew and Siassakos, Dimitrios and Thornton, Jim and Willis, Elaine and Woolfall, Kerry and Gamble, Carrol and Weeks, Andrew},
title = {Carboprost versus Oxytocin as the first-line treatment of primary postpartum haemorrhage (COPE): protocol for a phase IV, double-blind, double-dummy, randomised controlled trial and economic analysis},
journal = {BMJ Open},
year = {2025},
doi = {10.1136/bmjopen-2025-101255}
}
EUVIMED